MinorPolyene systemic antifungal×Opioid analgesic, phenylpiperidine class
Updated · Methodology
Mechanism
Pethidine is metabolised in the liver, and its main metabolite is norpethidine. Pethidine, norpethidine and other metabolites are excreted by the kidneys, and in renal impairment norpethidine excretion is delayed (Dolantina SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amphotericin B affects the kidneys: even the less toxic liposomal form can reduce renal function and cause potassium and magnesium loss, especially at high doses (AmBisome SmPC, AEMPS). The documents describe no interaction for the pair. Pethidine is not described as nephrotoxic, and amphotericin B is not one of the CYP3A4 inhibitors that raise pethidine concentrations (Demerol label, US Food and Drug Administration, FDA). On the contrary, the amphotericin B documents list pethidine among the drugs used to prevent and treat infusion-related reactions (AmBisome SmPC, AEMPS, and AmBisome label, FDA).
Symptoms
The documents describe no symptoms linked to this combination. Infusion-related reactions to amphotericin B are most often fever, chills and rigors, and less often chest pain or tightness, dyspnoea, bronchospasm, tachycardia and hypotension (AmBisome SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Pethidine causes drowsiness and dizziness and can depress breathing and lower blood pressure. When norpethidine accumulates, for example with prolonged use or renal impairment, neurotoxicity with seizures can occur (Dolantina SmPC, AEMPS; Demerol label, US Food and Drug Administration, FDA).
Management
According to the documents, the combination is acceptable, and the doses need no change. The liposomal amphotericin B documents themselves list pethidine among the measures that help prevent or treat infusion-related reactions, together with a slower infusion, diphenhydramine, paracetamol and hydrocortisone (AmBisome SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and AmBisome label, US Food and Drug Administration, FDA). During amphotericin B treatment, renal function, potassium and magnesium are checked regularly, and if renal function worsens significantly, dose reduction, interruption or discontinuation is considered (AmBisome SmPC, AEMPS). The pethidine dose is reduced in mild and moderate renal impairment, and pethidine is contraindicated in severe renal impairment (Dolantina SmPC, AEMPS). In renal impairment, the pethidine dose is titrated slowly (Demerol label, FDA). Prolonged use of increasing pethidine doses in renal impairment can cause neurotoxicity because of norpethidine (Dolantina SmPC, AEMPS). While pethidine is given, oxygen and ventilation equipment are kept available (Dolantina SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Demerol injection (meperidine) prescribing information (2026)– FDA, DailyMed, Hospira, setid b31d1308-28c3-43f4-e0a6-2f3ed76b8975, revised 07/2026, sections 4, 5.6, 5.8 and 7
- AEMPS: Ficha técnica AMBISOME LIPOSOMAL 50 MG POLVO PARA DISPERSION PARA PERFUSION (2024)– AEMPS. Ficha técnica AMBISOME LIPOSOMAL 50 MG POLVO PARA DISPERSION PARA PERFUSION (revisión 2024). CIMA, https://cima.aemps.es/cima/dochtml/ft/61117/FT_61117.html
- AEMPS: Ficha técnica: Petidina, Dolantina 50 mg/ml (nº registro 24245), sección 4.3 (2026)– AEMPS, CIMA, nº registro 24245 (Kern Pharma), revisión 07/2026, secciones 4.3, 4.4 y 4.5
- FDA: AmBisome (amphotericin B liposome) prescribing information (2026)– FDA, DailyMed setid f7be6506-4d20-401e-a0ff-02ad7c33158a (Astellas Pharma US), revised 10/2026 (version 14), Contraindications, Warnings, Precautions (Laboratory Tests, Drug Interactions) and Clinical Studies (infusion-related reactions)